Skip to content

Monopar Therapeutics MNPR Investment Purchases

Investment Purchases at other companies

Eli Lilly logo
Eli LillyLLY
$297M+50.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$131M
Prime Medicine logo
Prime MedicinePRME
$7.28M-84.9%
Perspective Therapeutics logo
Perspective TherapeuticsCATX
$150.34M+565%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$19.74M-81.0%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$64.38M+556%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's investment purchases?
Monopar Therapeutics (MNPR) reported investment purchases of $40.84M in Q1 2026.
How has Monopar Therapeutics's investment purchases changed year-over-year?
Monopar Therapeutics's investment purchases increased by 2020.5% year-over-year, from $1.93M to $40.84M.
What is the long-term trend for Monopar Therapeutics's investment purchases?
Over 2 years (2023 to 2025), Monopar Therapeutics's investment purchases has grown at a 232.3% compound annual growth rate (CAGR), from $7.89M to $87.15M.
What does investment purchases mean?
Cash spent purchasing investment securities across all categories.